TLSI Stock Forecast & Price Target

TriSalus Life Sciences is attractive fundamentally because its FDA-cleared TriNav PEDD platform addresses a clear clinical gap in liver embolization by improving selective delivery and tumor-to-normal exposure, while Advance clearance expands access to smaller vessels and could lift liver share toward 15%–20% from about 10%–15%. Commercial momentum also looks credible: 2025 revenue was $45.2M, 2Q26 revenue was $11.4M versus $10.3M consensus, gross margin reached 86.8%, and FY26 guidance of $54M–$57M implies continued growth despite a temporary sales-force reset. Longer term, the platform’s reimbursement portability, adjacent opportunities across a roughly $2.5B TAM, and nelitolimod’s partnership optionality support meaningful upside beyond the core liver franchise.

TriSalus Life Sciences is a highly dependent, single-product business because substantially all revenue comes from TriNav, leaving execution exposed to adoption, reimbursement, and regulatory setbacks. The company’s 1Q26 revenue of $8.9M fell 2.9% YoY, FY26 guidance was cut to $54M-$57M from $60M-$62M, and the TriNav Advance 510(k) delay removed expected 2026 revenue, underscoring weak near-term visibility. Its broader thesis is also constrained by limited commercialization, early-stage clinical evidence for nelitolimod, and the risk of future dilution because it is not yet profitable.